PepsDECLARED COMPOSITION
10 mg total- BPC-1575 mg
- TB-5005 mg
BPC-157 + TB-500 blend
A two-component listing with equal declared masses of BPC-157 and a TB-500-labeled component.
Exact blend study not appraisedProduct knowledge
Look inside the blend. Understand the ingredients, the identity questions, and which research actually applies.
Seven supplier-specific blend references are available now. Amounts are supplier declarations, not batch measurements. The same blend name can describe a different formulation elsewhere.
2 ingredients
DECLARED COMPOSITION
10 mg total- CJC-1295 no DAC5 mg
- Ipamorelin5 mg
CJC no DAC + ipamorelin blend
An equal-mass blend labeled CJC-1295 no DAC and ipamorelin; the no-DAC qualifier is essential.
Exact blend study not appraisedDECLARED COMPOSITION
70 mg total- GHK-Cu50 mg
- BPC-15710 mg
- TB-500 label · identity discrepancy10 mg
GLOW blend
A three-component listing: GHK-Cu, BPC-157, and a TB-500-labeled component. These notes apply to this supplier's 70 mg version.
Exact blend study not appraisedDECLARED COMPOSITION
80 mg total- GHK-Cu50 mg
- BPC-15710 mg
- TB-500 label · full-length description10 mg
- KPV10 mg
KLOW blend
A four-component listing adding KPV to GHK-Cu, BPC-157, and a TB-500-labeled component.
Exact blend study not appraisedDECLARED COMPOSITION
120 mg total- NAD+100 mg
- MOTS-c10 mg
- 5-Amino-1MQ10 mg
NAD+ / MOTS-c / 5-Amino-1MQ blend
A mixed-compound listing containing one peptide, MOTS-c, alongside NAD+ and 5-Amino-1MQ.
Exact blend study not appraisedDECLARED COMPOSITION
30 mg total- BPC-15710 mg
- TB-500 label · full-length description10 mg
- Cartalax10 mg
Regeno blend
A three-component listing with BPC-157, a TB-500-labeled component, and Cartalax in equal declared masses.
Exact blend study not appraisedDECLARED COMPOSITION
8 mg total- Tesamorelin6 mg
- Ipamorelin2 mg
Tesamorelin + ipamorelin blend
A two-component research listing with a declared 6 mg of tesamorelin and 2 mg of ipamorelin.
Exact blend study not appraised